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Background: Cerenkov luminescence imaging (CLI) is an emerging imaging technique where visible light emitted
from injected beta-emitting radionuclides is detected with an optical imaging device. CLI research has mostly been
focused on positive contrast imaging for ascertaining the distribution of the radiotracer in a way similar to other
nuclear medicine techniques. Rather than using the conventional technique of measuring radiotracer distribution,
we present a new approach of negative contrast imaging, where blood vessel attenuation of Cerenkov light
emitted by [68Ga]GaCl3 is used to image vasculature.
Methods: BALB/c nude mice were injected subcutaneously in the right flank with HT-1080 fibrosarcoma cells 14 to
21 days prior to imaging. On the imaging day, [68Ga]GaCl3 was injected and the mice were imaged from 45 to
90 min after injection using an IVIS Spectrum in vivo imaging system. The mice were imaged one at a time, and
manual focus was used to bring the skin into focus. The smallest view with pixel size around 83 μm was used to
achieve a sufficiently high image resolution for blood vessel imaging.
Results: The blood vessels in the tumor were clearly visible, attenuating 7% to 18% of the light. Non-tumor side
blood vessels had significantly reduced attenuation of 2% to 4%. The difference between the attenuation of light of
tumor vessels (10% ± 4%) and the non-tumor vessels (3% ± 1%) was significant. Moreover, a necrotic core confirmed
by histology was clearly visible in one of the tumors with a 21% reduction in radiance.
Conclusions: The negative contrast CLI technique is capable of imaging vasculature using [68Ga]GaCl3. Since blood
vessels smaller than 50 μm in diameter could be imaged, CLI is able to image structures that conventional nuclear
medicine techniques cannot. Thus, the negative contrast imaging technique shows the feasibility of using CLI to
perform angiography on superficial blood vessels, demonstrating an advantage over conventional nuclear medicine
techniques.
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Recent advances in medical imaging have led to new ad-
vances using existing technologies. An example of this al-
ternative use of existing technologies was the introduction
of Cerenkov luminescence imaging (CLI) by Robertson
et al. [1] and Spinelli et al. [2]. Robertson et al. demon-
strated that with the introduction of super-cooled charge-* Correspondence: steinberg137@gmail.com
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in any medium, provided the original work is pcoupled devices, it was possible to use optical imaging to
determine the distribution of positron emission tomo-
graphy (PET) radiotracers such as 2-deoxy-2-[18F]fluoro-
D-glucose (FDG) in vivo due to the emission of Cerenkov
light. Several groups have explored the possibilities of this
new medical imaging technique, including the use of other
radioisotopes and 3D reconstruction [3-5]. There have
also been a few groups that have tested the technique in
human subjects [6,7].
CLI has a few advantages over existing imaging tech-
nologies. Researchers have presented one advantage byis an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
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efficacy of drug therapy [8,9]. They argue that CLI pro-
vides a cheaper, faster alternative to PET due to the
ability to image five mice at the same time using an op-
tical imaging device. Another advantage that CLI has is
its ability to not only image the β+ emitting PET radio-
tracers, but also image β− emitting particles [6,10].
CLI has mainly been used as an alternative method for
imaging the distribution of PET tracers, but one can ac-
quire new anatomical information from CLI due to its
optical imaging properties. PET imaging detects the
gamma rays that result from the annihilation of the
emitted positron. The gamma rays pass through tissue
and most materials, allowing one to detect the location
of radiotracers deep within the body. CLI, on the other
hand, relies on Cerenkov light, which is produced from
positrons traveling faster than the speed of light within
the tissue. Thus, CLI detects activity at the site of the
decay of the radioisotope rather than the location of an-
nihilation of the positron, reducing the issue of positron
range, which limits the resolution of PET [11]. However,
CLI is limited in its detection ability since the Cerenkov
light gets attenuated and scattered by biological tissue,
making imaging of internal structures more difficult.
In this paper, we evaluate a new approach to CLI using
negative contrast imaging to image the light attenuated by
the blood vessels. In order to image the trace number of
photons attenuated by the blood, a radioisotope with high
Cerenkov light output was needed for adequate sensitivity.
Park et al. [12] and Beattie et al. [13] showed that 68Ga
had much higher Cerenkov light output than 18F, making
it an excellent candidate for negative contrast imaging.
Moreover, the gallium ion binds to plasma proteins re-
sulting in a thorough distribution throughout the body
[14,15]. The magnitude and distribution of light in the
body make [68Ga]GaCl3 an excellent compound for pro-




[68Ga]GaCl3 was obtained from an ITG
68Ge/68Ga gener-
ator (Isotope Technologies Garching, GmbH, Germany)
by elution with 10 mL 0.05 M HCl. After eluting and dis-
carding the first 0.5 mL, the following 2 mL of [68Ga]
GaCl3 was collected from the elution. The resulting [
68Ga]
GaCl3 (>99% radio purity) was neutralized using appro-
ximately 0.3 mL of 0.5 M NaOH to adjust pH to 7.0 ± 0.5,
and the formulated sample had an activity of 300 to
400 MBq/mL at the time of receipt.
Phantom study
[68Ga]GaCl3 was placed in plastic vials inside a well plate.
Vials contained anywhere from 0 to 90 μL of 68Ga withsaline added so that the total volume of each vial was
1 mL. The calculated activity of 68Ga in each vial ranged
from 0 to 0.61 MBq, which was decay-corrected to the
time of the scan. The phantom was scanned for 5 min on
a Caliper Life Sciences IVIS Spectrum in vivo imaging sys-
tem (PerkinElmer Life Sciences, Hopkinton, MA, USA).
The average photon emission of each sample was measured
after subtraction of cosmic radiation using a region of inter-
est (ROI) centered on the vial using Living Image 4.3.1 soft-
ware, and the radiance (p/s/cm2/sr) determined from the
ROI was decay-corrected. Using the same method, the
measurements were acquired using 0 to 7.44 MBq of [18F]
FDG. The average radiance versus activity of the radiotracer
was plotted for both radiotracers and fitted using a linear
regression. The slope of the linear fit was used to determine
the average radiance per activity for each radioisotope.Mouse model
All studies were approved by the Institutional Animal Care
and Use Committee of the Biological Resource Centre.
BALB/c nude mice were used in this study, and the
tumors were derived from HT-1080 human fibrosarcoma
acquired from the American Type Culture Collection
(ATCC; University Boulevard, Manassas, VA, USA). The
cells were cultured in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum and 1%
penicillin-streptomycin in a humidified incubator with 5%
CO2. Each mouse was injected subcutaneously with one
million cells suspended in 100 μL saline (0.9% NaCl). The
tumors were allowed to grow for 14 to 21 days reaching a
diameter of 6 to 10 mm. The growth characteristics of the
HT-1080 cell line in nude mice have been presented by
several researchers [16-18].Biodistribution
Nine female nude mice of 8 to 9 weeks old bearing HT-
1080 xenograft tumor were injected intravenously with 6
to 17 MBq in 100 μL of the formulated [68Ga]GaCl3. The
animals were warmed up in an incubator at 36°C for 30 to
40 min before injection. After 30, 65, and 120 min post
injection, a cardiac puncture using a needle and syringe
was done for exsanguination while under anesthesia with
oxygen and 2% isoflurane mixture. The euthanized mice
were dissected, the organs were weighed, and the radiation
in each organ was measured using a PerkinElmer gamma
counter. Radioactivity in the organs was determined by
calibrating the instrument with a standard curve with
a known activity of 68Ga. The radioactivity was decay-
corrected, and the results were expressed as percentage
injected dose per unit weight of the organ (%ID/g). The
biodistribution was also evaluated on an IVIS by placing
the organs inside a well plate in the scanner. The organs
were scanned for 5 min using view D with small binning
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0.45 mm× 0.45 mm pixel size, f/stop = f/1).
Positron emission tomography
In order to understand the in vivo behavior of [68Ga]GaCl3
radiotracer, a dynamic PET emission scan was performed
on a Siemens Inveon Positron Emission Tomography/Com-
puted Tomography (PET/CT) system (Siemens Health-
care USA, Inc., Malvern, PA, USA) over 120 min after
injection of 100 μL (20 MBq) of the radiotracer via the tail
vein. The acquired PET emission image was dynamically
rebinned with 20 frames of 20 s, 10 frames of 180 s, 10
frames of 300 s and 5 frames of 400 s using the Siemens
Inveon Research Workplace software. The anatomical
image acquired from CT was registered with the PET
image and the result was represented as %ID/g.
Cerenkov luminescence imaging
For the in vivo experiment, 13 mice were injected with
100 μL of the formulated [68Ga]GaCl3 (9 to 24 MBq) via
the tail vein. Shortly after injection, the mice were anesthe-
tized with an oxygen and isoflurane mixture (3% induction,
2% maintenance) and placed inside the IVIS. The manual
focus function of the IVIS was used to focus on the surface
of the skin prior to the scan, and a white light image of the
mouse was taken. The mice were scanned 45 to 90 min
after injection for a duration of 5 min, and only one mouse
per scan was done using view A with small binning
(4.0 cm × 4.0 cm field of view, 480 × 480 pixels, 0.083 mm×
0.083 mm pixel size, f/stop = f/1).
In order to qualitatively compare blood vessel attenuation
of Cerenkov light from [68Ga]GaCl3, 100 μL (9 to 13 MBq)
of [18F]FDG was injected into five mice. The mice were not
fasted prior to the [18F]FDG experiment in order to
minimize uptake to the tumor and allow for easier
visualization of vasculature. The mice were scanned 60 to
90 min after injection for 20 min, and only one mouse per
scan was done using view A with small binning. A 20-min
scan duration was used instead of 5 min in order to
partially compensate for the low radiance of Cerenkov light
for 18F.
All analyses of the CLI results were performed using Liv-
ing Image 4.3.1 software. The percentage of light attenuated
by the blood vessels was calculated by dividing the average
pixel value within a section of the blood vessel by the aver-
age pixel value to the immediate right and left of the blood
vessel using the same ROI. The amount of light attenuated
by the blood vessels on the tumor side and non-tumor side
was evaluated, and the significance was determined using
Student’s t test (two-tailed, 95% confidence interval).
Histology
After euthanasia, the skin samples were removed encom-
passing the tumor and the surrounding skin tissue. Thetissue samples were fixed in 4% paraformaldehyde and
were sent for histology the following day. Histology work
was performed in the Advanced Molecular Pathology La-
boratory, Institute of Molecular and Cell Biology, Agency
for Science, Technology and Research, Singapore. The wet
tissue was sectioned carefully to contain both the tumor
and blood vessels. The samples were cut in 5-μm-thick
sections, and the slides were stained with hematoxylin and
eosin (H&E).
The H&E slides were imaged using a Nikon SMZ18
microscope. The blood vessel diameter was determined
by measuring the short axis of the vessels from the
digital images taken by the microscope.
Results
Phantom results
A plot of the radiance per dose is shown in Figure 1. The
average radiance of [68Ga]GaCl3 based on the slope was
1.52 × 106 p/s/cm2/sr per MBq with an R2 value of 0.996.
The average radiance of [18F]FDG based on the slope was
1.28 × 105 p/s/cm2/sr per MBq with an R2 value of 0.997.
Thus, the radiance of 68Ga was approximately 11.9 times
higher than the radiance of 18F.
Biodistribution results
A plot of the biodistribution of nude mice taken at 30, 65,
and 120 min after injection is shown in Figure 2. The lar-
gest amount of radioactivity was found in the blood
followed by the liver and spleen. Tumor and intestinal up-
take were relatively low with negligible uptake in the
brain. At 65 min post-injection, the blood had a %ID/g
of 15%, indicating that 68Ga remained in the blood long
after injection. Even after 120 min, the blood still had the
highest %ID/g compared to the other tissues.
Figure 3 shows the biodistribution for one of the mice
using the IVIS. Figure 3b shows a bar graph comparing
the biodistribution of the IVIS versus the gamma counter
for two of the mice 65 min after injection with values nor-
malized to the thigh muscle. Figure 3c shows the ratio of
IVIS flux to radioactivity as measured by the gamma
counter normalized to muscle. The intestines, tumor,
brain, muscle, and femur had similar values for flux versus
decay activity, while the heart, lungs, spleen, liver, and kid-
neys had lower flux. The blood had the lowest Cerenkov
light output versus decay activity, and the total flux was
extremely low despite the blood having the highest decay
activity. The ratio of IVIS flux to gamma counter counts
was roughly 20 times lower than the same ratio for the
thigh muscle, indicating high attenuation of Cerenkov
light by the blood.
In vivo results
Figure 4 shows PET/CT images of [68Ga]GaCl3 from 0
to 120 min after injection. In the first few minutes after
Figure 1 Plot of radiance in p/s/cm2/sr versus activity in MBq of samples. Plot of radiance in p/s/cm2/sr of samples of varying levels of
activity of [68Ga]GaCl3 (blue) and [
18F]FDG (red) for a 5-min scan on an IVIS spectrum.
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from the heart. After 30 min, the tracer was distributed
throughout the body with clearance through the renal
system. The signal from the heart remained high for the
entire 120-min duration due to the circulation of 68Ga in
the blood.
Figure 5 shows a comparison of [18F]FDG and [68Ga]
GaCl3 imaging of the vasculature in mice at day 14 post-
injection of tumor cells. Figure 5a shows CLI of a mouse
with the corresponding photographic image below 75 min
after injection with 13 MBq of [18F]FDG, and Figure 5bFigure 2 Biodistribution of [68Ga]GaCl3 in mice 30, 65, and 120 min ashows CLI of a mouse with the corresponding photo-
graphic image below 50 min after injection with 14 MBq
of [68Ga]GaCl3. The activities at the time of each scan
were 8.1 MBq for [18F]FDG and 8.4 MBq for [68Ga]GaCl3,
and the total flux from each mouse was 3.4 × 106 p/s and
4.0 × 107 p/s, respectively. Thus, the amount of light pro-
duced per megabecquerel was 12.2 times higher for 68Ga
than 18F, matching the phantom measurements. Due to
the high photon attenuation of Cerenkov light of the
blood, the blood vessels were clearly observed in both
scans, with a 6% reduction in radiance due to the bloodfter injection. A gamma counter was used (three mice per group).
Figure 3 Comparison of IVIS and gamma counter biodistribution measurements for two of the mice. (a) The IVIS biodistribution of [68Ga]
GaCl3 in a mouse 65 min after injection. (b) Bar graph comparing the IVIS biodistribution in flux (photons/s) versus the gamma counter measurements
of the decay activity (gamma ray counts) normalized to the thigh muscle for two mice 65 min after injection. The intestines, tumor, brain, muscle, and
femur bone have similar values, but the heart, lungs, spleen, liver, blood, and kidneys show reduced flux relative to the activity. While the blood had
the highest activity of 6.2 times muscle, the Cerenkov light output was only 0.32 times muscle. (c) Ratio of IVIS flux to the gamma counter counts
normalized to muscle. Compared to muscle, the ratio of Cerenkov light to radioactivity was only 0.05, demonstrating that blood attenuated much
more light than the muscle and other organs.
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by the blood vessel entering the tumor in the [68Ga]GaCl3
scan. Moreover, a 12% reduction in radiance was observed
at the tumor core of the [18F]FDG scan, and an 18% re-
duction in radiance was seen at the tumor core in the
[68Ga]GaCl3 scan. Qualitatively, extensive vasculature in-
cluding major blood vessels and branching of the vesselscould be observed in the [68Ga]GaCl3 scan, whereas only
a single blood vessel could be seen in the [18F]FDG scan.
Figure 6 shows the tumor side and non-tumor side with
corresponding photographic images below for a mouse
90 min after injection with 20 MBq of [68Ga]GaCl3.
Although vasculature was visible on the tumor and non-
tumor sides of the animal, the amount of light attenuated
Figure 4 PET/CT images of [68Ga]GaCl3 distribution in nude mice shown from 0 to 120 min post-injection. The radiotracer was observed
to be distributed throughout the body and cleared through the renal system. The large signal from the heart indicates that much of the
radiotracer remained in the blood.
Figure 5 Comparison of [18F]FDG and [68Ga]GaCl3 imaging of the vasculature in mice. (a) CLI using [
18F]FDG on a day-14 fibrosarcoma
tumor with corresponding photographic image below. (b) CLI using [68Ga]GaCl3 for a day-14 fibrosarcoma tumor with corresponding photo-
graphic image below. The tumors are outlined in red. A blood vessel can be seen in the [18F]FDG image, resulting in a 6% reduction in radiance
outside the tumor and 12% reduction in the tumor core. However, the vasculature is much clearer and more elaborate in the [68Ga]GaCl3 image,
where the blood vessel in the tumor attenuated 9% of the Cerenkov light and the tumor core attenuated 18% of the Cerenkov light.
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Figure 6 Tumor side and non-tumor side CLI with corresponding photographic images. CLI using [68Ga]GaCl3 on a day 16 fibrosarcoma
tumor on (a) tumor side and (b) non-tumor side with corresponding photographic images below. The vasculature on the tumor side is more prominent,
with the lateral vessel entering the tumor attenuating 8% of the Cerenkov light, whereas the lateral vessel on the non-tumor side attenuated only 3% of
the Cerenkov light. The tumor is outlined with red enclosure.
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the tumor attenuated 8% of the Cerenkov light, whereas
the non-tumor side blood vessel attenuated only 3% of the
Cerenkov light.
Figure 7 shows an H&E stain and CLI of a 21-day post-
injection fibrosarcoma tumor, which had a blood vessel
leading into the core of the tumor similar to Figure 5. The
mouse was injected with 10 MBq of activity, and the
mouse was scanned at 90 min after injection. Figure 7a
shows a cross section of the tumor with H&E stain with
the major blood vessel and necrotic core visible. Figure 7b
shows a magnified image of a subcutaneous blood vessel
in the tumor, which appears dilated due to the presence of
the tumor. Figure 7c shows a magnified image of the
necrotic region with thin arrows indicating areas of high
accumulation of red blood cells and thick arrows indicat-
ing areas of necrosis. Figure 7d shows the CLI of the
mouse where the histology section was taken. The section
taken is indicated by the yellow line, and the outline of the
tumor is shown in red. The necrotic core is clearly seen in
the image with a 21% reduction in radiance, where the
accumulation of red blood cells in the necrotic area
caused high attenuation of the Cerenkov light. Figure 7d
also shows the dilated tumor blood vessel from Figure 7b,
which attenuated 12% of the Cerenkov light.Figure 8 shows highly vascularized tumors with promi-
nent blood vessels. Figure 8a shows CLI with correspond-
ing photographic image below of a mouse 45 min after
injection with 24 MBq of [68Ga]GaCl3, and Figure 8b
shows CLI with corresponding photographic image below
of a mouse 60 min after injection with 11 MBq of [68Ga]
GaCl3.
For the 13 mice scanned, the tumor and non-tumor
sides were imaged and the attenuation of light from the
blood vessels was measured. The tumor blood vessels
attenuated 7% to 18% of the light for an average atte-
nuation of 11% ± 4%, whereas the lateral vein on the
non-tumor side of the mouse running the length of the
body attenuated 2% to 4% of the light for an average at-
tenuation of 3% ± 1%. The difference was significant with
a p value of 1.0 × 10−5.
Discussion
Using the negative contrast imaging technique, it was
possible to use CLI to image the blood vessels in nude
mice due to the high absorption of red and infrared light
by the red blood cells compared to the surrounding tis-
sue [19]. We observed in Figure 3 that different organs
had different light attenuation properties, and the blood
had particularly high photon attenuation. Our results
Figure 7 H&E stain and CLI of a 21-day post-injection fibrosarcoma tumor. (a) H&E stained histology sample showing the tumor with necrotic
core and large blood vessel. (b) H&E stained histology sample showing a magnified section of a large subcutaneous blood vessel. (c) H&E stained
histology sample showing a magnified section of the necrotic core. The accumulation of red blood cells within the necrotic core is indicated by the
thin arrows, while the white spaces showing the location of cell necrosis are indicated by the thick arrows. (d) CLI of the mouse from where the H&E
stain was taken as indicated by the yellow line with the tumor outlined in red. The necrotic core and the large blood vessel entering the tumor are
clearly seen with 21% and 12% reduction in radiance, respectively.
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ting in reduced signal in the blood vessels and the nec-
rotic area of the tumor as seen in Figure 7d. Although
the blood contains a large proportion of the radiotracer
(6.2 times muscle), Figure 3 shows that the resulting
Cerenkov light from the blood is quite low (0.32 times
muscle). Thus, the blood vessels are visualized since the
combined Cerenkov light output of all deeper tissues
results in a full body backlighting, which is attenuated
by the blood in the blood vessels before reaching the
camera, resulting in a negative contrast. The tumor
blood vessels attenuate more light than non-tumor
blood vessels primarily due to the larger diameter of the
dilated vessels, which results in greater attenuation due
to the increased amount of blood the light must travel
through.
In this paper, we used [68Ga]GaCl3 as a CLI tracer due
to its characteristically high light output and long blood
circulation time. When injected intravenously, [68Ga]
GaCl3 provided background illumination that allowed for
visualization of the anatomical structures that had higher
attenuation of light than surrounding tissues. We propose
that visualization of blood vessels is possible since blood
attenuates more Cerenkov light than the surrounding tis-
sue. Cerenkov light is emitted at all frequencies in thevisual light range but produces more photons at shorter
wavelengths of light, resulting in the characteristically blue
color of Cerenkov light. Since blue light is greatly atte-
nuated by biological tissues, Cerenkov light emitted from
mice injected with [68Ga]GaCl3 will mostly consist of lon-
ger wavelength photons such as red and infrared light.
Since the blood, and especially venal blood, attenuates
more light in the red region than surrounding tissue [20],
negative contrast of blood vessels is possible.
For our study, we used HT-1080 fibrosarcoma tumors
for imaging blood vessels, which greatly expresses VEGF/
VPF under both normoxic and hypoxic conditions [21].
Angiogenesis observed in solid xenograft tumors leads to
co-option of neighboring tissues, resulting in dilation of
existing normal vessels [22-24]. The dilation of these
blood vessels is an important consequence of tumor de-
velopment which is primarily absent on the contralateral
(i.e., non-tumor) side. CLI provides visualization of such
vessels as a result of attenuation of the background-
illuminated Cerenkov radiation. Additionally, the necrotic
core of tumors, typically characterized by dead tissue due
to hypoxic conditions [25], has greater attenuation of light
compared to surrounding tumor tissue primarily due to
the accumulation of blood in the necrotic regions as seen
in Figure 7c.
Figure 8 CLI of highly vascularized tumors with prominent blood vessels. CLI using [68Ga]GaCl3 for subcutaneous fibrosarcoma models at
day 21 below with hypervascularization of tumors (outlined in red) with scans taken (a) 45 min after injection of 24 MBq and (b) 60 min after
injection of 11 MBq with corresponding photographic images below.
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could possibly be performed with other radiotracers,
[68Ga]GaCl3 was optimal for blood vessel imaging for a
few reasons. One reason is that 68Ga has very high light
output with nearly 12 times the light output of 18F, which
allowed for imaging with high sensitivity. As seen in
Figure 5, the blood vessel light attenuation was observed
using both [68Ga]GaCl3 and [
18F]FDG, but the image
quality was much better using [68Ga]GaCl3 with much
more extensive vasculature visible. The poor image quality
of [18F]FDG was likely due to the greatly reduced radiance
that could only be partially compensated with longer ex-
posure time (20 min vs. 5 min). Using the same imaging
parameters as [68Ga]GaCl3 (5 min exposure and small
binning) resulted in no discernible blood vessels when
[18F]FDG was injected. The data suggest that other ra-
diotracers with high Cerenkov light output, such as 90Y
and 32P, could also be used for negative contrast imaging
of the blood vessels. Another reason for using [68Ga]GaCl3
for blood vessel imaging is that the radiotracer remains in
the blood for a long period after injection as observed in
the biodistribution shown in Figure 2. Moreover, the
dynamic PET/CT in Figure 4 shows a high signal in the
heart even though the biodistribution shows fairly low up-
take in the heart, so it can be concluded that 68Ga stayed
in the blood with minimal uptake in the myocardium.Since light is scattered and attenuated by the tissue, the
radiance at the surface as observed by the IVIS camera
was fairly evenly distributed even though the distribution
observed using PET was not as uniform. The distribution
of radiotracer allowed for an adequate amount of light to
visualize blood vessels near the surface of the skin from
the neck to flank.
There are a number of factors to consider when per-
forming negative contrast CLI of blood vessels. One factor
is the source of Cerenkov light providing the backlighting
necessary for negative contrast imaging of the blood ves-
sels. Since the radiotracer is distributed throughout the
body, light is emitted from all directions relative to the
blood vessels. That means that superficial blood vessels,
which are typically 0.2 to 0.4 mm under the surface of the
skin, can be poorly delineated due to both light emitted
from the radiotracer and the scattering of light between
the blood vessel and the surface of the animal. As a result,
the objects at the surface of the animal, such as fur, are
clearly delineated, whereas deeper blood vessels cannot be
visualized at all. With the most optimal focusing, the
width of the blood vessels in the CLI images was about
0.4 mm, which was approximately 10 times the actual
blood vessel diameter. Respiration was also a factor in
image quality. Although mice were positioned so that mo-
tion in the x and y directions was minimized, respiratory
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sels to move in and out of focus resulting in blurring. One
way to minimize the blurring effect of respiration is to re-
duce the aperture size (i.e., f/stop). Reducing the aperture
size from f/1 to f/2 can provide sharper images of the
blood vessels by allowing for a greater depth of focus.
However, a reduction of f/stop from f/1 to f/2 results in a
4-time reduction in the signal, which requires a longer ex-
posure time. Thus, it was determined that there was little
qualitative improvement in reducing the aperture size
since the blood vessels will be in focus for most of the
respiratory cycle, so signal was maximized by choosing an
f/stop of f/1.
There are some potential applications for imaging vas-
culature with CLI. The angiogenic behavior of tumors is
a highly researched topic [26], and imaging of the blood
vessels near the surface has been proven useful using
techniques such as intravital microscopy [27]. Other po-
tential applications that our research has demonstrated
are the use of negative contrast CLI to detect necrosis
within subcutaneous tumors and measurements of the
dilation of tumor blood vessels. Although the blood ves-
sels could be seen with the naked eye as well as in the
photographs, CLI has the potential advantage of quanti-
fying blood vessel dilation through measurements of the
attenuation of Cerenkov light by the blood vessel.
Figure 6 demonstrates the advantage of using CLI for
imaging blood vessels because CLI could not only image
both tumor and non-tumor blood vessels, but it could
also measure the difference via attenuation of Cerenkov
light. This study consistently showed higher light attenu-
ation from blood vessels in or on the tumor than blood
vessels on the non-tumor side. Whereas typical subcuta-
neous blood vessels are 10 to 50 μm in diameter [28,29],
tumor blood vessel diameters can exceed 100 μm, which
was the case for the mouse in Figure 7. The dilated
tumor blood vessels attenuated more Cerenkov light
than the non-dilated, non-tumor side blood vessels since
Cerenkov light passes through more blood in the larger
diameter blood vessels. It was observed that tumor ves-
sels attenuated approximately three times more light at
10% ± 4% than the non-tumor side vessels at 3% ± 1%.
Qualitatively, the blood vessels on the tumor side were
much clearer and easier to delineate than the non-tumor
side blood vessels.
The photon attenuation of blood vessels has been ob-
served in other techniques, such as intravital microscopy,
and the absorption properties of blood are well-known
[20]. The high photon absorption of the blood resulted in
greater attenuation in the blood vessels than the sur-
rounding tissue, which allowed for imaging of blood
vessels and areas of blood accumulation. For example,
histology confirmed red blood cell accumulation inside
the tumor in Figure 7c with a 21% reduction of radianceat the tumor core as shown in Figure 7d. Thus, CLI could
identify necrosis within the tumor since accumulation of
red blood cells is one of the characteristics of a necrotic
core [30]. The reason for the lack of positive signal from
the blood vessels despite the presence of 68Ga in the blood
was that the amount of radiance caused by the positron
decays of 68Ga was insignificant compared to the high
attenuation of Cerenkov light in the blood as observed in
Figure 3. The cumulative effect of all photons emitted
from internal tissues created a whole body internal illu-
mination that acted as a system of background lighting,
which allowed for negative contrast imaging of superficial
structures such as the blood vessels.Conclusions
Using [68Ga]GaCl3, it was possible to image vasculature in
mice with CLI. The high light output and the distribution
of [68Ga]GaCl3 within the body make the radiotracer an
excellent tool for blood vessel imaging. Negative contrast
imaging is different from conventional CLI techniques,
which typically look at areas of high uptake of the radio-
tracer similar to other nuclear medicine techniques. By
taking advantage of the optical properties of CLI, a new
approach of negative contrast imaging can be done. Not
only is it possible to image the distribution of the radioiso-
tope, but it is also possible to image subcutaneous blood
vessels. Our data show that imaging of blood vessels is
feasible using a radiotracer with high Cerenkov light out-
put, which could potentially lead to the development of
CLI for angiography.Competing interests
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